Mead Johnson Nutrition Reports Second Quarter and First Half 2016 Results; Reaffirms 2016 EPS Guidance; Announces an Expansion of Cost Productivity Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BMO Capital Remains Bullish on Mead Johnson (MJN) Following 2Q Report
July 29, 2016 9:22 AM EDTBMO Capital reiterated an Outperform rating with a $97.00 price target on Mead Johnson Nutrition (NYSE: MJN) following the company's 2Q earnings report. MJN reported EPS of $0.88, above $0.81 estimates. The company reiterated EPS guidance of $3.48-3.60.
Analyst Amit Sharma commented, "MJN reported 2Q16 adjusted EPS of $0.88,... More
Societe Generale Downgrades Mead Johnson Nutrition (MJN) to Hold
July 29, 2016 6:52 AM EDTSociete Generale downgraded Mead Johnson Nutrition (NYSE: MJN) from Buy to Hold with a price target of $95.00 (from $100.00).
For an analyst ratings summary and ratings history on Mead Johnson Nutrition click here. For more ratings news on Mead Johnson Nutrition click here.
Shares of Mead Johnson Nutrition closed at $89.89 yesterday.
... MoreMead Johnson (MJN) Tops Q2 EPS by 10c, Sales Miss; Reaffirms EPS Outlook
July 28, 2016 7:43 AM EDTMead Johnson (NYSE: MJN) reported Q2 EPS of $0.88, $0.10 better than the analyst estimate of $0.78. Revenue for the quarter came in at $941.5 million versus the consensus estimate of $963.66 million.
"As we move through this year, I am pleased that we continue to deliver against our... More

